

Philip S J Weston

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7676223/publications.pdf>

Version: 2024-02-01

47
papers

1,375
citations

516710

16
h-index

477307

29
g-index

50
all docs

50
docs citations

50
times ranked

2873
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer's disease: a longitudinal cohort study. <i>Molecular Psychiatry</i> , 2021, 26, 5967-5976.	7.9	76
2	Plasma amyloid- β ratios in autosomal dominant Alzheimer's disease: the influence of genotype. <i>Brain</i> , 2021, 144, 2964-2970.	7.6	16
3	Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease. <i>Journal of Internal Medicine</i> , 2021, 290, 583-601.	6.0	54
4	Visual short-term memory impairments in presymptomatic familial Alzheimer's disease: A longitudinal observational study. <i>Neuropsychologia</i> , 2021, 162, 108028.	1.6	7
5	Visuomotor integration deficits are common to familial and sporadic preclinical Alzheimer's disease. <i>Brain Communications</i> , 2021, 3, fcab003.	3.3	8
6	Accelerated long-term forgetting: Prognostic utility in familial Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
7	Longitudinal (¹⁸ F)AV-1451 PET imaging in a patient with frontotemporal dementia due to a Q351R MAPT mutation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 106-108.	1.9	8
8	Quantitative detection and staging of presymptomatic cognitive decline in familial Alzheimer's disease: a retrospective cohort analysis. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 126.	6.2	13
9	Measuring cortical mean diffusivity to assess early microstructural cortical change in presymptomatic familial Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 112.	6.2	18
10	Plasma phospho-tau in familial Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e042921.	0.8	0
11	Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 19.	6.2	65
12	O3-03-01: THE SEQUENCE AND TIMING OF PRECLINICAL COGNITIVE DECLINE IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P882.	0.8	1
13	Reduced acquisition time PET pharmacokinetic modelling using simultaneous ASL-MRI: proof of concept. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 2419-2432.	4.3	11
14	Accelerated long-term forgetting in presymptomatic autosomal dominant Alzheimer's disease: a cross-sectional study. <i>Lancet Neurology</i> , The, 2018, 17, 123-132.	10.2	84
15	O2-04-04: LONGITUDINAL MEASUREMENT OF SERUM NEUROFILAMENT LIGHT CONCENTRATION IN FAMILIAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P623.	0.8	0
16	P1-524: VISUAL SHORT-TERM BINDING DEFICIT IN FAMILIAL ALZHEIMER'S DISEASE: A LONGITUDINAL STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P532.	0.8	1
17	P3-261: SERUM NEUROFILAMENT LIGHT CONCENTRATION AND PROGRESSION IN FAMILIAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1174.	0.8	0
18	Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 32.	6.2	79

#	ARTICLE	IF	CITATIONS
19	Molecular biomarkers of Alzheimer's disease: progress and prospects. DMM Disease Models and Mechanisms, 2018, 11, .	2.4	163
20	Direct Parametric Reconstruction With Joint Motion Estimation/Correction for Dynamic Brain PET Data. IEEE Transactions on Medical Imaging, 2017, 36, 203-213.	8.9	25
21	Serum neurofilament light in familial Alzheimer disease. Neurology, 2017, 89, 2167-2175.	1.1	204
22	[P2â€™458]: VISUOMOTOR INTEGRATION IN PRESYMPTOMATIC FAMILIAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P815.	0.8	1
23	[Icâ€™Pâ€™150]: CHARACTERISING PRESYMPTOMATIC ATROPHY PATTERNS THROUGH MULTIVARIATE MACHINE LEARNING. Alzheimer's and Dementia, 2017, 13, P113.	0.8	0
24	[P2â€™241]: CSF NEUROGRANIN IS INCREASED IN FAMILIAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P703.	0.8	0
25	[O1â€™02â€™02]: CHARACTERISING PRESYMPTOMATIC ATROPHY PATTERNS THROUGH MULTIVARIATE MACHINE LEARNING. Alzheimer's and Dementia, 2017, 13, P185.	0.8	0
26	[F4â€™01â€™04]: NEUROIMAGING AND HETEROGENEITY IN FAMILIAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P1211.	0.8	0
27	[O4â€™02â€™04]: SERUM NEUROFILAMENT LIGHT CONCENTRATION IN FAMILIAL ALZHEIMER'S DISEASE AND ASSOCIATION WITH MARKERS OF DISEASE STAGE AND SEVERITY. Alzheimer's and Dementia, 2017, 13, P1230.	0.8	0
28	Processing of Self versus Non-Self in Alzheimerâ€™s Disease. Frontiers in Human Neuroscience, 2016, 10, 97.	2.0	9
29	Diagnosing Dementia in the Clinical Setting: Can Amyloid PET Provide Additional Value Over Cerebrospinal Fluid?. Journal of Alzheimer's Disease, 2016, 54, 1297-1302.	2.6	21
30	P2-144: Model-Based Comparison of Autosomal-Dominant and Late-Onset Alzheimer's Disease Progression in the Dian and ADNI Studies. , 2016, 12, P668-P669.		4
31	O2-04-05: Accelerated Long-Term Forgetting in Presymptomatic Familial Alzheimerâ€™s Disease. , 2016, 12, P231-P231.		2
32	F5â€™02â€™02: Longitudinal Atrophy in Autosomal Dominant Ad and Sporadic Ad: Lessons from Dian. Alzheimer's and Dementia, 2016, 12, P368.	0.8	0
33	Presymptomatic cortical thinning in familial Alzheimer disease. Neurology, 2016, 87, 2050-2057.	1.1	58
34	Clinical phenotype and genetic associations in autosomal dominant familial Alzheimerâ€™s disease: a case series. Lancet Neurology, The, 2016, 15, 1326-1335.	10.2	163
35	IC-P-117: A cortical signature of familial Alzheimer's disease: Cross-sectional and longitudinal study of presymptomatic changes. , 2015, 11, P80-P81.		0
36	P1-191: Using florbetapir F18 PET to validate CSF cut-points and increase diagnostic certainty in atypical dementias. , 2015, 11, P421-P422.		0

#	ARTICLE	IF	CITATIONS
37	Do cerebrospinal fluid transfer methods affect measured amyloid β 242, total tau, and phosphorylated tau in clinical practice?. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 380-384.	2.4	5
38	Using florbetapir positron emission tomography to explore cerebrospinal fluid cut points and gray zones in small sample sizes. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 440-446.	2.4	16
39	Diffusion imaging changes in grey matter in Alzheimer's disease: a potential marker of early neurodegeneration. Alzheimer's Research and Therapy, 2015, 7, 47.	6.2	132
40	Factors Associated With the Onset and Persistence of Post-Lumbar Puncture Headache. JAMA Neurology, 2015, 72, 325.	9.0	59
41	IC-P-118: Measurement of cortical mean diffusivity detects early microstructural breakdown of the cerebral cortex in presymptomatic familial Alzheimer's disease. , 2015, 11, P81-P81.		0
42	O2-01-05: A cortical signature of familial Alzheimer's disease: Cross-sectional and longitudinal study of presymptomatic changes. , 2015, 11, P173-P174.		0
43	Discrimination of voice gender in the human auditory cortex. NeuroImage, 2015, 105, 208-214.	4.2	23
44	The use of mini-CEX in UK foundation training six years following its introduction: Lessons still to be learned and the benefit of formal teaching regarding its utility. Medical Teacher, 2014, 36, 155-163.	1.8	48
45	IC-P-175: LONGITUDINAL VOLUMETRIC AND DIFFUSION TENSOR IMAGING IN FAMILIAL ALZHEIMER'S DISEASE. , 2014, 10, P97-P98.		0
46	O1-07-02: LONGITUDINAL VOLUMETRIC AND DIFFUSION TENSOR IMAGING IN FAMILIAL ALZHEIMER'S DISEASE. , 2014, 10, P141-P142.		0
47	Metastatic bladder transitional cell carcinoma presenting as a vascularised cutaneous right arm lesion. International Journal of Clinical Oncology, 2012, 17, 286-289.	2.2	1